CubeSmart (CUBE)
(Real Time Quote from BATS)
$53.35 USD
-0.65 (-1.20%)
Updated Sep 19, 2024 12:46 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CUBE 53.35 -0.65(-1.20%)
Will CUBE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CUBE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CUBE
ESRT or CUBE: Which Is the Better Value Stock Right Now?
CubeSmart (CUBE) Meets Q2 FFO Estimates
CUBE: What are Zacks experts saying now?
Zacks Private Portfolio Services
ESRT or CUBE: Which Is the Better Value Stock Right Now?
Are Options Traders Betting on a Big Move in CubeSmart (CUBE) Stock?
CubeSmart (CUBE) Meets Q1 FFO Estimates
Other News for CUBE
CubeSmart price target raised by $9 at Jefferies, here's why
Peering Into CubeSmart's Recent Short Interest
CubeSmart price target raised by $1 at Evercore ISI, here's why
CubeSmart downgraded to Neutral as UBS sees limited valuation upside
Moderna, Halliburton downgraded: Wall Street's top analyst calls